Pfizer Stock Is Doing Something It Hasn't Done Since 2022

Pfizer (NYSE: PFE) stock hasn't made for a good investment over the past five years. It has declined by 25% in value over that stretch, while the S&P 500 has climbed by 68%. Investors have lost confidence in the company's ability to grow, as it loses patent protection on key drugs and faces an uncertain future. Besides a dividend, there hasn't been a compelling reason for investors to buy shares of Pfizer. But this year, with there being more concern in the markets and investors piling into dividend stock ...